Jean-Paul Clozel down­plays re­cruit­ment de­lays hold­ing up PhI­II for Fab­ry dis­ease

Idor­sia may have run in­to a bit of de­lay with the Phase III reg­is­tra­tional tri­al for one of its lead pro­grams, but CEO Jean-Paul Clozel is not fuss­ing about it.

Re­cruit­ment in­to a study of lucera­s­tat — which treats Fab­ry dis­ease by in­hibit­ing glu­co­syl­ce­ramide syn­thase — is slow­er than ex­pect­ed, push­ing the Swiss biotech to al­ter the ex­pect­ed com­ple­tion date to 2021.

“It’s not like we are los­ing with lucera­s­tat very pre­cious years of mar­ket­ing,” Clozel told Reuters af­ter a Q3 up­date. “Or­phan drugs are pro­tect­ed, and the pro­tec­tion starts when the prod­uct is on the mar­ket.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER